Human epidermal growth factor receptor 2 (HER2) expression dynamics between diagnosis and recurrence in patients with breast cancer using artificial intelligence and electronic health records: the RosHER study

E. López-Miranda , P. Tolosa-Ortega , M.A. Perelló-Martorell , L. Sánchez-Lorenzo , C. Hinojo-González , S. Servitja , S. Recalde-Penabad , C. Olier-Gárate , J.A. Guerrero , S. García-Vicente , L. Mina , D. Alcalá-López , L. López-Montero , C. Jiménez-Cortegana , M. Sampayo-Cordero , G. Antonarelli , J.M. Pérez-García , J. Cortés , A. Llombart-Cussac
{"title":"Human epidermal growth factor receptor 2 (HER2) expression dynamics between diagnosis and recurrence in patients with breast cancer using artificial intelligence and electronic health records: the RosHER study","authors":"E. López-Miranda ,&nbsp;P. Tolosa-Ortega ,&nbsp;M.A. Perelló-Martorell ,&nbsp;L. Sánchez-Lorenzo ,&nbsp;C. Hinojo-González ,&nbsp;S. Servitja ,&nbsp;S. Recalde-Penabad ,&nbsp;C. Olier-Gárate ,&nbsp;J.A. Guerrero ,&nbsp;S. García-Vicente ,&nbsp;L. Mina ,&nbsp;D. Alcalá-López ,&nbsp;L. López-Montero ,&nbsp;C. Jiménez-Cortegana ,&nbsp;M. Sampayo-Cordero ,&nbsp;G. Antonarelli ,&nbsp;J.M. Pérez-García ,&nbsp;J. Cortés ,&nbsp;A. Llombart-Cussac","doi":"10.1016/j.esmorw.2024.100107","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Human epidermal growth factor receptor 2 (HER2) is a treatment target in breast cancer (BC), driving therapeutic strategies. Changes over time in HER2 expression have been described and understanding of these fluctuations is crucial for personalized medicine. We aimed to assess HER2 expression dynamics using real-world data and natural language processing (NLP) from electronic health records (EHRs).</div></div><div><h3>Material and methods</h3><div>RosHER is a retrospective, observational, longitudinal, population-based, multicenter study (NCT05217381). An NLP tool extracted HER2 information from EHRs of adult patients with early, locally advanced, or <em>de novo</em> metastatic BC, who were initially diagnosed between 2005 and 2021. The primary endpoint was to evaluate HER2 dynamics in HER2 status and expression between initial diagnosis and recurrence or progression using NLP. The secondary endpoints were description of baseline clinicopathological characteristics and treatment patterns.</div></div><div><h3>Results</h3><div>Between January 2022 and November 2023, 18 533 patients were selected from seven Spanish sites. A cut-off of ≥6 months was established between initial determination and relapse or progression. The artificial intelligence (AI)-based tool identified 510 patients with two documented HER2 determinations and 209 with HER2 expression by immunohistochemistry/<em>in situ</em> hybridization. Overall discordances were 10.6% in HER2 status and 34.0% in HER2 expression. HER2-zero expression switched to HER2-low (23.2%), but not HER2-positive (0%); HER2-low expression converted to HER2-zero (32.0%) and HER2-positive (7.0%); finally HER2-positive expression switched to HER2-low (20.8%) and HER2-zero (15.1%).</div></div><div><h3>Conclusions</h3><div>This is the first study using NLP to evaluate HER2 discordances, which need to be further investigated. Improving AI methods and implementing similar EHR structures among hospitals would increase the success in clinical data extraction.</div></div>","PeriodicalId":100491,"journal":{"name":"ESMO Real World Data and Digital Oncology","volume":"7 ","pages":"Article 100107"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ESMO Real World Data and Digital Oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2949820124000857","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/16 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Human epidermal growth factor receptor 2 (HER2) is a treatment target in breast cancer (BC), driving therapeutic strategies. Changes over time in HER2 expression have been described and understanding of these fluctuations is crucial for personalized medicine. We aimed to assess HER2 expression dynamics using real-world data and natural language processing (NLP) from electronic health records (EHRs).

Material and methods

RosHER is a retrospective, observational, longitudinal, population-based, multicenter study (NCT05217381). An NLP tool extracted HER2 information from EHRs of adult patients with early, locally advanced, or de novo metastatic BC, who were initially diagnosed between 2005 and 2021. The primary endpoint was to evaluate HER2 dynamics in HER2 status and expression between initial diagnosis and recurrence or progression using NLP. The secondary endpoints were description of baseline clinicopathological characteristics and treatment patterns.

Results

Between January 2022 and November 2023, 18 533 patients were selected from seven Spanish sites. A cut-off of ≥6 months was established between initial determination and relapse or progression. The artificial intelligence (AI)-based tool identified 510 patients with two documented HER2 determinations and 209 with HER2 expression by immunohistochemistry/in situ hybridization. Overall discordances were 10.6% in HER2 status and 34.0% in HER2 expression. HER2-zero expression switched to HER2-low (23.2%), but not HER2-positive (0%); HER2-low expression converted to HER2-zero (32.0%) and HER2-positive (7.0%); finally HER2-positive expression switched to HER2-low (20.8%) and HER2-zero (15.1%).

Conclusions

This is the first study using NLP to evaluate HER2 discordances, which need to be further investigated. Improving AI methods and implementing similar EHR structures among hospitals would increase the success in clinical data extraction.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
人表皮生长因子受体2 (HER2)在乳腺癌患者诊断和复发之间的表达动态使用人工智能和电子健康记录:RosHER研究
人表皮生长因子受体2 (HER2)是乳腺癌(BC)的一个治疗靶点,推动着治疗策略的发展。已经描述了HER2表达随时间的变化,了解这些波动对于个性化医疗至关重要。我们的目的是利用来自电子健康记录(EHRs)的真实世界数据和自然语言处理(NLP)来评估HER2表达动态。材料和方法rosher是一项回顾性、观察性、纵向、基于人群的多中心研究(NCT05217381)。NLP工具从2005年至2021年间首次诊断为早期、局部晚期或新发转移性BC的成年患者的电子病历中提取了HER2信息。主要终点是评估HER2在初始诊断和使用NLP复发或进展期间的状态和表达动态。次要终点是基线临床病理特征和治疗模式的描述。结果在2022年1月至2023年11月期间,从西班牙7个地点选择了18533名患者。在初始检测和复发或进展之间建立了≥6个月的截止时间。基于人工智能(AI)的工具鉴定了510例有两项记录的HER2检测,209例通过免疫组织化学/原位杂交检测出HER2表达。HER2状态的总体不一致性为10.6%,HER2表达的总体不一致性为34.0%。her2零表达转化为her2低表达(23.2%),但不转化为her2阳性(0%);her2低表达转化为her2零表达(32.0%)和her2阳性表达(7.0%);最终her2阳性表达转换为her2低表达(20.8%)和her2零表达(15.1%)。这是首次使用NLP评估HER2不一致性的研究,有待进一步研究。改进人工智能方法并在医院之间实施类似的电子病历结构将提高临床数据提取的成功率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Empathic and agentic artificial intelligence in nursing: perspectives on a human-centered framework for cancer care navigation in the United States Artificial intelligence in medicine: a scoping review of the risk of deskilling and loss of expertise among physicians Optimisation and validation of line-of-therapy advancement algorithms in advanced/metastatic non-small-cell lung cancer: an I-O Optimise study Opportunities and challenges in implementing digital patient-centred cancer care in Europe—a qualitative study of several ESMO Designated Centres The role of socioeconomic position in use of systemic anticancer therapy
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1